Pyrilutamide
Experimental scalp compound for hair loss (KX-826); not proven in humans and not approved anywhere.

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

Related comparisons
Clascoterone vs Pyrilutamide vs RU58841DETAILED OVERVIEW
What is Pyrilutamide?
Pyrilutamide (KX-826) is an experimental compound for hair loss, applied to the scalp, developed by a company called Kintor Pharmaceutical. It is mainly being studied for hormone-related hair thinning (androgenetic alopecia), in both men and women. It is not approved anywhere and can only be used in clinical trials.
It stops DHT (dihydrotestosterone, a strong male hormone) from acting on hair follicle cells, so in principle it may slow the gradual shrinking of the follicles. Because it works locally, in principle it should not cause the side effects of anti-hormone drugs that act on the whole body. It is not proven to work in humans: clinical trials are under way, but there are still few efficacy results published in scientific journals. In the trials, mild redness, itching, flaking and dryness occurred on the scalp, but long-term safety is not known. It is to be avoided in pregnancy, because as a male-hormone blocker it could in principle harm the development of a male baby.
Development code
KX-826 (Kintor Pharmaceutical)
Status
Clinical trials (phase 2/3, hair loss); not approved anywhere
Mechanism of action
Topical androgen-receptor antagonist (local anti-DHT)
Form studied
Topical solution (e.g. 0.5% / 1.0%, 1-2x daily)
Evidence
Early/mid-phase; published efficacy still lacking
No anecdote collected yet.
Data console
Lab data
Kintor Pharmaceutical . KX-826 (pyrilutamide) topical solution in male androgenetic alopecia – phase 2 trial (US). ClinicalTrials.gov NCT05218642.
Kintor Pharmaceutical . KX-826 (pyrilutamide) phase 3 trial in adult male AGA patients. ClinicalTrials.gov NCT06126965.
Maheld J, et al. . Safety of Antiandrogens for the Treatment of Female Androgenetic Alopecia with Respect to Gynecologic Malignancies. J Clin Med. 2024. (class context: antiandrogens in AGA).
Safety
Side effects, stop signs, contraindications
Side effects · 3
- Local scalp reactions: in the trials the most common are mild application-site erythema, itching, flaking or dryness; usually mild and transient.
- Limited long-term safety data: as the compound is INVESTIGATIONAL (phase 2/3), the long-term safety profile is not yet complete; peer-reviewed published data are sparse.
- Systemic antiandrogen effect minimized by design: the intended advantage is LOCAL action (low systemic absorption), but the full human safety picture awaits ongoing trials.
Contraindications · 3
- Not an approved drug, investigational: routine use outside a clinical trial is not advised – there is no approved therapeutic indication.
- Pregnancy and childbearing potential without precautions: as an androgen-receptor antagonist it may pose a theoretical risk to male fetal development; avoid in pregnancy.
- Broken, inflamed scalp; known hypersensitivity to the active or the vehicle.
Related Hair & Skin
Same therapeutic category
Studies
Related research and clinical findings
KX-826 (pyrilutamide) topical solution in male androgenetic alopecia – phase 2 trial (US)
Kintor Pharmaceutical
KX-826 (pyrilutamide) phase 3 trial in adult male AGA patients
Kintor Pharmaceutical
Safety of Antiandrogens for the Treatment of Female Androgenetic Alopecia with Respect to Gynecologic Malignancies
Maheld J, et al.
Telegram
Have a question about Pyrilutamide?
Educational hair and skin info from official sources (PubMed, FDA, EMA). Does NOT replace medical consultation. Talk to a dermatologist!
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.